

Clinical Research Institute HUCH  
Sponsored, fully signed Clinical Trial Agreements (except grants)



Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)
January		x				x
January	x		NightstaRx Ltd	A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)	Head and Neck Center	
January	x		Novartis Finland Oy	An open-label, multi-center, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia who are eligible for "7+3" or "5+2" chemotherapy	Comprehensive Cancer Center	
January	x		Orion Pharmaceuticals	Safety and Pharmacokinetics of ODM-208 in Patients with Metastatic Castration-resistance Prostate Cancer	Comprehensive Cancer Center	
January	x		Insel Gruppe AG	Solitaire™ with the intention for thrombectomy plus intravenous t-PA versus direct Solitaire™ stent-retriever thrombectomy in acute anterior circulation stroke (SWIFT DIRECT)	Head and Neck Center	
February	x		Kyowa Kirin International	X-Linked Hypophosphatemia Registry	Children and Adolescents	
February	x		Essential Medical Inc.	Post-Market Clinical Registry to Evaluate the Safety and Performance of MANTA Vascular Closure Device Under Real World Conditions in the European Union	Heart and Lung Center	
February	x					x
February	x		Dr. Falk Pharma GmbH	Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis	Abdominal Center	

Clinical Research Institute HUCH  
Sponsored, fully signed Clinical Trial Agreements (except grants)



Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)
March		x				x
March	x		Chordate Medical AB	A clinical investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the treatment of Non Allergic Rhinitis (KOSNAR)	Head and Neck Center	
March	X		Santen	Ciclosporin 1 mg/ml eye drop emulsion (Ikervis <sup>®</sup> ) for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes: Clinical effectiveness, tolerability and safety in a real world setting.	Head and Neck Center	
March	x					x
March	x		Anylam Pharmaceuticals Inc.	ALN-ASI-003 A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias	Internal Medicine and Rehabilitation	
March	x		Insel Gruppe AG	Early versus late initiation of direct oral anticoagulants in post-ischaemic stroke patients with atrial fibrillation (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trial	Head and Neck Center	
March	x		COMPASS Pathways Ltd.	The safety and efficacy of Psilocybin in participants with treatment-resistant depression (P-TRD)	Psychiatry Center	

Clinical Research Institute HUCH  
Sponsored, fully signed Clinical Trial Agreements (except grants)



Year 2018

1.		2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)	
March	x		Incyte Corporation	A randomized, double-blind, placebo-controlled phase 3 study of Itacitinib or placebo in combination with corticosteroids for the treatment of first-line acute graft versus-host disease (GRAVITAS-301)	Comprehensive Cancer Center, Hematology		
March	x		Boehringer-Ingelheim	Safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in patients with idiopathic pulmonary fibrosis (IPF) on no background anti-fibrotic (Part 1) and safety and tolerability of BI 1015550 on top of Nintedanib and Pirfenidone (Part 2).	HUCH Heart and Lung Center		
April	x						x
April	x		Celgene Corporation	A PHASE 1 MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-92480 IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA	Comprehensive Cancer Center		
April	x						x
May		x	Oulu Univeristy	Assessment of brain dysfunction in intensive care patients by analyzing propofol-induced EEG changes	Perioperative, Intensive Care and Pain Medicine		
May	x						x

Clinical Research Institute HUCH  
Sponsored, fully signed Clinical Trial Agreements (except grants)



Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)
May		x	Aarhus University Hospital/Institute of Clinical Medicine Aarhus University Hospital	NOR-GRASPALL – Single-Arm PK/PD and safety study of GRASPA for patients with hypersensitivity to PEG-Asparaginase, diagnosed with Ph(-) Acute Lymphoblastic Leukemia	Children and Adolescents	
May	x		Bristol-Myers Squibb	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma	Comprehensive Cancer Center	
May	x		Deciphera Pharmaceuticals, LLC	A Phase 3, InterVentional, Double-Blind, Placebo Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with Advanced Gastrointestinal Stromal Tumors who have Received Treatment with Prior Anticancer Therapies	Comprehensive Cancer Center	
May	x		Novo Nordisk Farma Oy	Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity	Abdominal Center	
June	x		F Hoffmann-La Roche Limited	A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer Immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy	Comprehensive Cancer Center	











Clinical Research Institute HUCH  
Sponsored, fully signed Clinical Trial Agreements (except grants)



Year 2018

1.	2. The Study is		3.	4.	5.	6.
Month when the Agreement was signed	a) Sponsored Study	b) Investigator initiated Study	Study Sponsor	Full name of the Study	Name of the Helsinki University Hospital clinic where the Study is being conducted (if more than one clinic, please choose the main clinic only)	The sponsor is not willing to publish details of the Study (If this is marked with X, sections 3, 4, and 5 are left blank)